

Mount Sinai -- Clopidogrel Alerts

IPM PGx Projects

Created: Summer 2013

Revised: Version 3, May 2015

Version 2 effective: September 2014

Version 3 effective: May 2015

Clopidogrel Order

CYP2C19 genotype available in CLIPMERGE

Yes

No

Do not FIRE BPA

CYP2C19 UM

CYP2C19 EM

CYP2C19 IM

CYP2C19 PM

1. Do not fire BPA
2. File genetic result

1. Do not fire BPA
2. File genetic result

1. Fire BPA #1
2. File BPA text as result
3. File genetic result

1. Fire BPA #2
2. File BPA text as result
3. File genetic result

Clopidogrel BPA #1

A.

“Clopidogrel Order” **PLUS** “CYP2C19 *1/*2 Genotype”

This patient has been prescribed Clopidogrel and is a **CYP2C19 Intermediate Metabolizer (*1/*2)** according to genetic testing. Intermediate Metabolizer status is associated with diminished antiplatelet response to Clopidogrel, and increased risk for adverse cardiovascular events following percutaneous coronary intervention (PCI).

If this patient is undergoing/has undergone PCI and there is no contraindication, consider alternative treatment from the CLIPMERGE SmartSet.

To ignore this advice and proceed with the original order, please select an acknowledgement reason and click Accept.

[Click here](#) for further information. The medications in the CLIPMERGE SmartSet may not be appropriate for this patient. Click the Lexi-Comp links in the CLIPMERGE SmartSet for further medication information including indication, dosage and contraindications.

For further assistance: contact us at 646-823-7860 or clipmergeteam@mssm.edu

Clopidogrel BPA #2

B.

“Clopidogrel Order” PLUS “CYP2C19 *2/*2 Genotype”

This patient has been prescribed Clopidogrel and is a *CYP2C19 Poor Metabolizer (*2/*2)* according to genetic testing. Poor Metabolizer status is associated with significantly diminished antiplatelet response to Clopidogrel, and increased risk for adverse cardiovascular events following percutaneous coronary intervention (PCI).

If this patient is undergoing/has undergone PCI and there is no contraindication, consider alternative treatment from the CLIPMERGE SmartSet.

To ignore this advice and proceed with the original order, please select an acknowledgement reason and click Accept.

[Click here](#) for further information. The medications in the CLIPMERGE SmartSet may not be appropriate for this patient. Click the Lexi-Comp links in the CLIPMERGE SmartSet for further medication information including indication, dosage and contraindications.

For further assistance: contact us at 646-823-7860 or clipmergeteam@mssm.edu